CHICAGO, Illinois: AbbVie will acquire Apogee Therapeutics for $10.9 billion, gaining an experimental treatment for inflammatory diseases as it looks to reinforce its immunology business ahead of future patent expirations. The deal, announced on June 22, is AbbVie's largest acquisition in more than five years and one of the biggest biotechnology transactions of the year. AbbVie will pay US$135.11 for each